Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Kaitlin J. Mayne, Jennifer B. Green, Natalie Staplin(University of Oxford), David Z.I. Cherney(University Health Network), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), David Preiss(Pontificia Universidad Católica de Chile), Emily Sammons(University of Oxford), Doreen Zhu, William G. Herrington(Oxford Health NHS Foundation Trust), Martin Landray(Gentofte Hospital), Roberto Pontremoli(Ospedale Policlinico San Martino), Sibylle J. Hauske(Heidelberg University), Richard Haynes, Adeera Levin(University of British Columbia), Parminder K. Judge(University of Oxford), Rebecca J. Sardell(University of Miami)
Cited by 24
Related Papers
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k